CD274 and Merkel cell skin cancer: Navtemadlin (KRT-232) is another MDM2 inhibitor that is being investigated with or without anti–PD-1/anti–programmed death-ligand 1 (PD-L1) therapy in a phase 1b/2 trial (NCT03787602) in adult patients with Merkel cell carcinoma.